Pipeline

Basilea has a broad pipeline of innovative drugs with well differentiated and competitive profiles to treat drug-resistant bacterial infections, systemic fungal infections and drug-resistant tumors. Basilea’s anti-infectives isavuconazole and ceftobiprole are in late-stage clinical development, while the novel antibiotic BAL30072 and the oncology compound BAL101553 are in clinical phase 1.

A European Marketing Authorization Application for ceftobiprole for the treatment of pneumonia in the hospital has been accepted for review in October 2012. 

Toctino® (alitretinoin) was developed and brought to market by Basilea. Basilea entered into a global agreement on Toctino® with Stiefel, a GSK company, in June 2012.